Abstracts tagged "Antinucleosome antibodies and systemic lupus erythematosus (SLE)"

Abstract Number: 2546 • 2013 ACR/ARHP Annual Meeting
Anti-Nucleosome Antibodies As a Predictor Factor For Relapses In Clinically Quiescent Systemic Lupus Erythematosus: Results Of a Prospective Cohort Study
Dalia Sanchez-Mosco¹, Nadia Alejandra Gandarilla-Martinez², Nicte Selene Fajardo-Robledo³, Valeria Diaz-Rizo⁴, Soraya Amali Zavaleta-Muñiz⁵, Miguel Huerta⁶, Xochitl Trujillo⁶, Arnulfo Nava⁷, Ernesto German Cardona-Muñoz⁸, Jose Francisco Muñoz-Valle⁹, Jorge Ivan Gamez-Nava¹⁰ and Laura Gonzalez-Lopez¹¹, ¹Centro Universitario de Investigación Biomédica, Universidad de Colima; Hospital General Regional 110 IMSS, Guadalajara, Jalisco, Mexico, ²Departamento de Medicina Interna/Reumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, ³Fisiología, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ⁴Doctorado en Ciencias Médicas, Centro Universitario de Investigación Biomédica, Universidad de Colima; UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ⁵UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS; Doctorado en Ciencias con orientación en Inmunología, Guadalajara, Jalisco, Mexico, ⁶Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, ⁷UMAE, Hospital de Especialidades Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ⁸Unidad de Investigación Cardiovascular, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ⁹Doctorado en Ciencias Biomédicas. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ¹⁰UMAE, Centro Médico Nacional de Occidente, IMSS; Doctorado en Farmacología, Universidad de Guadalajara, Jalisco, Mexico, ¹¹Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico
Background/Purpose: A significant number of studies have identified a correlation between anti-nucleosome antibodies (AN-ab) and disease activity in SLE; nevertheless, there is a lack of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].